Enlivex Therapeutics Ltd.
ENLV
$1.00
-$0.01-0.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.48% | -15.13% | -19.97% | -32.43% | -26.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.62% | -32.39% | -38.23% | -39.99% | -30.79% |
| Operating Income | 18.62% | 32.39% | 38.23% | 39.99% | 30.79% |
| Income Before Tax | 41.25% | 44.88% | 48.35% | 30.30% | 17.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.25% | 44.88% | 48.35% | 30.30% | 17.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.25% | 44.88% | 48.35% | 30.30% | 17.22% |
| EBIT | 18.62% | 32.39% | 38.23% | 39.99% | 30.79% |
| EBITDA | 17.23% | 31.91% | 38.35% | 40.74% | 31.50% |
| EPS Basic | 51.56% | 53.01% | 53.23% | 32.40% | 18.38% |
| Normalized Basic EPS | 43.07% | 46.33% | 48.56% | 48.70% | 34.76% |
| EPS Diluted | 51.09% | 52.71% | 53.27% | 32.51% | 18.53% |
| Normalized Diluted EPS | 43.07% | 46.33% | 48.56% | 48.70% | 34.76% |
| Average Basic Shares Outstanding | 21.09% | 16.86% | 10.42% | 5.41% | 2.07% |
| Average Diluted Shares Outstanding | 21.09% | 16.86% | 10.42% | 5.41% | 2.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |